Search the Newsreel

DO & CO Aktiengesellschaft (VIE:DOC) hat soeben die Ergebnisse des ersten Quartals veröffentlicht: Das prognostizieren Analysten für dieses Jahr

Die secunet Security Networks Aktiengesellschaft (ETR:YSN) hat soeben ihre Halbjahresergebnisse veröffentlicht, und Analysten passen ihre Prognosen an.

Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress

Nektar Therapeutics' stock fell 4% following its Q2 2026 earnings report, despite progress in its autoimmune pipeline, notably rezpegaldesleukin. The market reacted negatively to the company's substantial cash burn, with a quarterly net loss exceeding US$40 million and trailing 12-month losses widening. While the …

Lang & Schwarz Aktie: 36 Prozent Erholung seit Juli-Tief

Plan Group Financial LLC Takes Position in Oaktree Specialty Lending Corp. $OCSL

Plan Group Financial LLC has acquired a new position in Oaktree Specialty Lending Corp. (OCSL), purchasing over 202,000 shares valued at approximately $2.42 million. This investment represents a 0.23% stake in the company, which saw its institutional ownership reach 36.79%. Despite beating earnings per …

OKTA Stock Records Biggest Ever Single-Day Gains, Blasts Past Wall Street’s Latest Price Targets After Q1 Beat

Okta, Inc. - Class A Common Stock (NQ: OKTA)

This page provides recent news headlines related to Okta, Inc. (OKTA), including articles on options activity, market support, security issues, and analyst ratings. Many articles discuss Okta's stock performance, particularly in March 2025, highlighting surges due to strong earnings and analyst upgrades, as well …

Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise

NEKTAR THERAPEUTICS Q2 2026: Revenue $10.1M, EPS $(1.23) — 10-Q Summary

NEKTAR THERAPEUTICS reported Q2 2026 results with revenue of $10.1 million and a net loss of $40.6 million, an improvement from the $41.6 million loss in the prior year. The diluted loss per share was $(1.23). The company highlighted advancements in its pipeline, including …

Nektar Therapeutics Q2 Earnings Call Highlights

Nektar Therapeutics announced the initiation of its global Phase III ZENITH AD program for rezpegaldesleukin (REZPEG) in moderate-to-severe atopic dermatitis, with top-line data expected in mid-2028 and a potential BLA submission in 2029. The company also finalized plans for a registrational Phase III trial …

Jack In The Box (JACK) Stock Fair Value Rises After Split Analyst Views

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price targets for Jack in the Box now sit in a wide band of about US$12 to US$22, which highlights how differently analysts are …

Two Seas Capital group (NKTR) reports 9.1% Nektar Therapeutics ownership via investment funds

Two Seas Capital group, including Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi, has reported a 9.1% beneficial ownership stake in Nektar Therapeutics (NKTR). As of June 30, 2026, they collectively own 3,092,234 shares of common stock through investment funds, …

Daktronics (DAKT) Stock Dropped, What Is Driving Attention Now?

Daktronics (DAKT) has recently seen its stock price decline by about 3% in the past day and 6% in the past week, yet it maintains positive momentum over longer periods. The company is considered materially undervalued, with a fair value of around $30.67 against …

Lang & Schwarz Aktie: 3,00 Euro Dividende gefordert

OCSL|Oaktree Specialty Lending Corp|Price:13.021|Chg%:-0.039

KT Corp announces BRK1TCBDR007 dividend of R$ 0.81 per unit

KT Corporation has declared a gross dividend of R$ 0.81 per unit for the third quarter of 2026. Shares will trade with entitlement through July 27, 2026, and payment is scheduled for August 26, 2026. This news brief was generated by Public Technologies (PUBT) …

Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch

Akenerji Elektrik Uretim AS (AKENR) Forumu

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

Nektar Therapeutics NKTR reported a loss of $1.23 per share for the second quarter of 2026, much narrower than the Zacks Consensus Estimate of a loss of $2.06. In the year-ago quarter, the company had incurred a loss of $2.95 cents per share. Total …

Sakthi Sugars Q1FY26 net loss widens to ₹18.3 crore as revenue grows 25%

Kawhi Leonard Investigation Takes New Turn as Leaked Emails Emerge

Leaked emails have revealed that Los Angeles Clippers personnel facilitated contact between Kawhi Leonard's representatives and Daktronics, a company involved in the team's arena. This discovery adds a new dimension to the NBA's ongoing investigation into Leonard's financial arrangements and potential salary cap circumvention, …

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Okta (OKTA) Stock Looks Pricey On Cash Flow And Earnings

Okta’s AI‑Native Identity Push And MCP Cost Controls Could Be A Game Changer For Okta (OKTA)

Earlier this week, Citizens JMP Securities upgraded Okta to "Market Outperform," highlighting the company's expanded AI-focused identity security capabilities, including its Permiso Security acquisition, new partnerships, and recently enhanced products geared toward securing AI agents. Okta also introduced identity-scoped Model Context Protocol tool lists …

JTEKT India issues RPT compliance certificate after audit review

Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss

Sakthi Sugars Q1 FY27 Results: Revenue Rs 376 Cr, Net Loss Rs 1 Cr

Following Wynca Group and Hubei Xingfa's Expansion in IDA-Based Synthesis Routes, New Study Projects $1.1 Billion Phosphorus Trichloride Market for Glyphosate

Company Logo Sustained global demand for crop protection products and broader adoption of low-waste synthesis routes, highlighted by process optimizations and capacity positioning across Wynca Group, Hubei Xingfa Chemicals Group Co., Ltd., LANXESS AG, ICL Group, and Xuzhou Yongda Chemical Co., Ltd. are driving …

Orge Enerji (ORGE) hisseleri için bilanço sonrası hedef fiyat açıklandı

Nektar: Q2 Earnings Snapshot

The article provides a snapshot of Nektar's Q2 earnings. No specific financial details are available in the provided content, as the main article text was not included.

Massive Update for Okta Stock Investors

I have had Okta(NASDAQ: OKTA) stock ranked as a buy for several years. Missed Nvidia in 2009? This Rare Signal Is Flashing Again.In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total …

JTEKT India Q1 Results: Net profit falls 41% YoY to ₹6.22 crore

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

Earnings Call Insights: Nektar Therapeutics (NKTR) Q2 2026 MANAGEMENT VIEW * “In July, we achieved yet another important milestone in Nektar with the initiation of the global ZENITH AD program, Phase III AD program for rezpegaldesleukin” (CEO, President & Director Howard W. Robin). “With …